Lassiter Wright III 4

What Happened
Lassiter Wright III, a director of Quest Diagnostics (DGX), was granted 1,142 shares via an award on 2026-05-20. The Form 4 reports the acquisition as 1,142 shares at $0.00 (an award of restricted stock units), indicating a compensation/award transaction rather than an open-market purchase.

Key Details

• Transaction date: 2026-05-20; Form 4 filed: 2026-05-21 (timely filing).
• Transaction type/code: A (award/grant/acquisition).
• Shares granted: 1,142; reported acquisition price: $0.00.
• Footnotes: F1 = represents restricted stock units (RSUs). F2 = amount includes shares acquired via dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors since the last Form 4.
• Shares owned after the transaction: not specified in the provided filing.
• No indication this was an option exercise, sale, or 10b5-1 plan; this is a compensation award.

Context
RSU awards are typically part of director compensation and subject to vesting and plan terms; they are not an open-market buy or sell. The $0.00 price reflects that these were granted, not purchased; any tax or vesting implications depend on plan rules and are separate from trading intent.